These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35405720)

  • 1. Association Between Loss of SATB2 Expression in Inflammatory Bowel Disease Indefinite for Dysplasia and a Diagnosis of Definitive Dysplasia on Follow-up.
    Cretara A; Knee A; Mueller J; Jawale R
    Am J Surg Pathol; 2022 Aug; 46(8):1137-1141. PubMed ID: 35405720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of SATB2 Expression Is a Biomarker of Inflammatory Bowel Disease-associated Colorectal Dysplasia and Adenocarcinoma.
    Ma C; Henn P; Miller C; Herbst C; Hartman DJ; Pai RK
    Am J Surg Pathol; 2019 Oct; 43(10):1314-1322. PubMed ID: 31318711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
    Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
    Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
    Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
    Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SATB2 is a Promising Biomarker for Identifying a Colorectal Origin for Liver Metastatic Adenocarcinomas.
    Zhang YJ; Chen JW; He XS; Zhang HZ; Ling YH; Wen JH; Deng WH; Li P; Yun JP; Xie D; Cai MY
    EBioMedicine; 2018 Feb; 28():62-69. PubMed ID: 29396302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermucinous, Goblet Cell-Deficient and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up.
    Choi WT; Salomao M; Zhao L; Alpert L; Setia N; Liao X; Drage MG; Westerhoff M; Cheng J; Lauwers GY; Ko HM
    J Crohns Colitis; 2022 Jan; 16(1):98-108. PubMed ID: 34232295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
    Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
    Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SATB2 loss in inflammatory bowel disease-associated small intestinal metaplasia of the distal colon.
    Zeineldin M; Larman TC
    bioRxiv; 2023 Feb; ():. PubMed ID: 36778374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease.
    Derikx LA; Kievit W; Drenth JP; de Jong DJ; Ponsioen CY; Oldenburg B; van der Meulen-de Jong AE; Dijkstra G; Grubben MJ; van Laarhoven CJ; Nagtegaal ID; Hoentjen F;
    Gastroenterology; 2014 Jan; 146(1):119-28.e1. PubMed ID: 24076060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SATB2 is a supplementary immunohistochemical marker to CDX2 in the diagnosis of colorectal carcinoma metastasis in an unknown primary.
    Dabir PD; Svanholm H; Christiansen JJ
    APMIS; 2018 Jun; 126(6):494-500. PubMed ID: 29924451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma.
    Skalova A; Sar A; Laco J; Metelkova A; Miesbauerova M; Steiner P; Švajdler M; Michal M
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):140-146. PubMed ID: 27258560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Risk of Non-conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
    Zhang R; Lauwers GY; Choi WT
    J Crohns Colitis; 2022 Dec; 16(12):1825-1834. PubMed ID: 35771958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SATB2 in Neoplasms of Lung, Pancreatobiliary, and Gastrointestinal Origins.
    De Michele S; Remotti HE; Del Portillo A; Lagana SM; Szabolcs M; Saqi A
    Am J Clin Pathol; 2021 Jan; 155(1):124-132. PubMed ID: 32914850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Young investigator challenge: Cadherin-17 and SATB2 in cytology specimens: Do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins?
    Brandler TC; Jelloul FZ; Soto D; Das K; Rosen L; Bhuiya TA
    Cancer Cytopathol; 2015 Dec; 123(12):706-13. PubMed ID: 26671737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant expression of maspin in idiopathic inflammatory bowel disease is associated with disease activity and neoplastic transformation.
    Cao D; Wilentz RE; Abbruzzese JL; Ho L; Maitra A
    Int J Gastrointest Cancer; 2005; 36(1):39-46. PubMed ID: 16227634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of SATB2 immunostaining in the distinction between small intestinal and colorectal adenocarcinomas.
    Kim CJ; Baruch-Oren T; Lin F; Fan XS; Yang XJ; Wang HL
    J Clin Pathol; 2016 Dec; 69(12):1046-1050. PubMed ID: 27169755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
    Strickland S; Parra-Herran C
    Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma.
    Elebro J; Heby M; Gaber A; Nodin B; Jonsson L; Fristedt R; Uhlén M; Jirström K; Eberhard J
    J Transl Med; 2014 Oct; 12():289. PubMed ID: 25323550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - Single institution experience.
    Kamarádová K; Vošmiková H; Rozkošová K; Ryška A; Tachecí I; Laco J
    Pathol Res Pract; 2019 Apr; 215(4):730-737. PubMed ID: 30679085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.